Discover how a $9 billion IPO and a subsequent US ban highlight the staggering production gap in humanoid technology. Learn why China's factory in Hefei is outpacing every US lab combined, and what this means for the AI arms race. Chapters: 00:00 $9B IPO, 48-Hour Ban 00:12 No Manufacturing Answer 00:25 Unitree revenue surge 00:36 Innovation vs. Scale 00:48 Market Confidence 00:58 The 48-Hour Ban 01:14 Ban Doesn't Stop Unitree 01:31 US vs. China Output 01:41 The Missing Factory 01:52 Scale vs. Innovation 02:03 US Lab Brilliance 02:21 Entity List: US Export License Required 02:34 US vs. Unitree Output 02:48 The IPO Trigger 03:04 Hefei's Independence 03:20 Robot+ in Action 03:36 The Cost of Scale 03:52 Government Targets 04:08 The Talent Pipeline 04:24 No US Factory Yet 04:40 The Final Stakes Sources & further reading: • Unitree Robotics IPO filing — Hong Kong Stock Exchange filing, late 2024 • US Department of Commerce Entity List — Bureau of Industry and Security, December 2024 • Reuters coverage of Unitree ban — December 2024 article on the Entity List addition • MarketsandMarkets report on humanoid robots — Market forecast for humanoid robots • World Intellectual Property Organization (WIPO) patent data — Humanoid robot patents by country • Unitree official website — Product specs and company information











